Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection Pub Date : 2025-02-01 DOI:10.1016/j.jinf.2025.106423

Shuo Feng , Sagida Bibi , Parvinder K. Aley , Federica Cappuccini , Elizabeth A. Clutterbuck , Kerry Conlin , Narges Ebrahimi , Agnes Eordogh , Saul N. Faust , Sally Felle , Justin Green , Hardeep Gill , Yama Mujadidi , Iyiola Oladunjoye , Nelly Owino , Emma Plested , Hannah Robinson , Arabella Stuart , Merryn Voysey , Andrew J. Pollard , Teresa Lambe

{"title":"Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study","authors":"Shuo Feng , Sagida Bibi , Parvinder K. Aley , Federica Cappuccini , Elizabeth A. Clutterbuck , Kerry Conlin , Narges Ebrahimi , Agnes Eordogh , Saul N. Faust , Sally Felle , Justin Green , Hardeep Gill , Yama Mujadidi , Iyiola Oladunjoye , Nelly Owino , Emma Plested , Hannah Robinson , Arabella Stuart , Merryn Voysey , Andrew J. Pollard , Teresa Lambe","doi":"10.1016/j.jinf.2025.106423","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2.</div></div><div><h3>Methods</h3><div>COV009 is a safety follow-up study of volunteers enroled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study, 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19. Primary outcomes were reactogenicity, safety, and humoral immunogenicity. Anti-spike IgG and pseudo-neutralising antibody against multiple variants were measured from pre-first dose to 28 days post-second and post-fourth dose (third dose samples were unavailable).</div></div><div><h3>Results</h3><div>A fourth dose of ChAdOx1 nCoV-19 had an acceptable safety profile with no vaccine-related serious adverse events. Humoral responses against various SARS CoV-2 variants post-fourth dose were significantly increased compared with the responses after the second dose (7- to 9-fold increase for anti-spike IgG responses across variants, all p<0.05). Those with lower antibody levels prior to the 4th dose had stronger responses to a 4th dose booster. Seropositivity by anti-nucleocapsid, or higher antibody responses pre-fourth dose correlated with lower infection risks six months thereafter (OR: 0.16, 95% CI: 0.05, 0.50).</div></div><div><h3>Conclusions</h3><div>The ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 2","pages":"Article 106423"},"PeriodicalIF":14.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163445325000179","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2.

Methods

COV009 is a safety follow-up study of volunteers enroled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study, 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19. Primary outcomes were reactogenicity, safety, and humoral immunogenicity. Anti-spike IgG and pseudo-neutralising antibody against multiple variants were measured from pre-first dose to 28 days post-second and post-fourth dose (third dose samples were unavailable).

Results

A fourth dose of ChAdOx1 nCoV-19 had an acceptable safety profile with no vaccine-related serious adverse events. Humoral responses against various SARS CoV-2 variants post-fourth dose were significantly increased compared with the responses after the second dose (7- to 9-fold increase for anti-spike IgG responses across variants, all p<0.05). Those with lower antibody levels prior to the 4th dose had stronger responses to a 4th dose booster. Seropositivity by anti-nucleocapsid, or higher antibody responses pre-fourth dose correlated with lower infection risks six months thereafter (OR: 0.16, 95% CI: 0.05, 0.50).

Conclusions

The ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.

查看原文本刊更多论文

ChAdOx1 nCoV-19疫苗在两次ChAdOx1 nCoV-19和第三次BNT162b2 （COV009）后作为第四剂加强剂的安全性和体液免疫原性：一项前瞻性队列研究

目的：评估ChAdOx1 nCoV-19作为第四剂增强剂在接种了两剂初始疫苗和第三剂BNT162b2的个体中的安全性和体液免疫原性。方法：COV009是一项纳入关键许可前ChAdOx1 nCoV-19志愿者的安全性随访研究。在这项亚研究中，149名符合条件的参与者接受了第四剂ChAdOx1 nCoV-19。主要结果为反应原性、安全性和体液免疫原性。从第一次给药前到第二次和第四次给药后28天（没有第三次给药样本）测量抗刺突IgG和抗多种变异的伪中和抗体。结果：第四剂ChAdOx1 nCoV-19具有可接受的安全性，没有与疫苗相关的严重不良事件。与第二次给药相比，第四次给药后对各种SARS CoV-2变体的体液应答显著增加（抗刺突IgG应答增加7- 9倍）。结论：ChAdOx1 nCoV-19第四次给药耐受性良好，可增强体液免疫；这是明显的，增加的体液反应在多种变体的关注。这些数据支持将其用作对抗SARS-CoV-2感染的加强剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection 医学-传染病学

CiteScore

45.90

自引率

3.20%

发文量

475

审稿时长

16 days

期刊介绍： The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection. Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.